MedPath

Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
Associated Therapies
-

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
Interventions
First Posted Date
2023-04-25
Last Posted Date
2024-10-31
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT05828303
Locations
🇪🇸

Local Institution - 2138, Madrid, M, Spain

🇺🇸

Local Institution - 2102, Denver, Colorado, United States

🇺🇸

Gabrail Cancer Center Research, Canton, Ohio, United States

and more 36 locations

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Phase 1
Completed
Conditions
Overweight Subjects
Obese Subjects
Interventions
First Posted Date
2023-04-18
Last Posted Date
2023-11-14
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
48
Registration Number
NCT05815680
Locations
🇨🇳

Aerospace Center Hospital, Beijing, Beijing, China

A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-03-29
Last Posted Date
2023-11-14
Lead Sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Target Recruit Count
54
Registration Number
NCT05789342
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, China

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

First Posted Date
2023-03-14
Last Posted Date
2023-07-13
Lead Sponsor
AstraZeneca
Target Recruit Count
6
Registration Number
NCT05768360
Locations
🇩🇪

Research Site, Berlin, Germany

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Not Applicable
Recruiting
Conditions
Liver Cirrhosis
Interventions
First Posted Date
2023-02-23
Last Posted Date
2024-11-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT05741372
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo matching BI 1839100
Drug: BI 1839100
Drug: midazolam
Drug: digoxin
Drug: rosuvastatin
First Posted Date
2023-02-22
Last Posted Date
2024-11-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
67
Registration Number
NCT05738291
Locations
🇳🇱

ICON-Groningen-62040, Groningen, Netherlands

Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Supaglutide injection
Drug: Digoxin
Drug: Metformin
First Posted Date
2023-01-23
Last Posted Date
2024-08-05
Lead Sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Target Recruit Count
34
Registration Number
NCT05694221
Locations
🇨🇳

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2022-10-28
Last Posted Date
2022-10-28
Lead Sponsor
Amgen
Target Recruit Count
14
Registration Number
NCT05598281
Locations
🇺🇸

Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Phase 1
Completed
Conditions
Pain
Interventions
First Posted Date
2022-09-15
Last Posted Date
2024-03-20
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
37
Registration Number
NCT05541471
Locations
🇺🇸

Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Phase 1
Completed
Conditions
Multi Drug Resistant Tuberculosis
Drug Sensitive Tuberculosis
Pulmonary Disease
Drug-resistant Tuberculosis
Mycobacterium Tuberculosis Infection
Tuberculosis, Pulmonary
Tuberculosis
Interventions
First Posted Date
2022-09-02
Last Posted Date
2024-10-07
Lead Sponsor
Global Alliance for TB Drug Development
Target Recruit Count
28
Registration Number
NCT05526911
Locations
🇺🇸

TKL Research, Inc., Fair Lawn, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath